Related Experiment Videos
Assessment of therapeutic control of anticoagulation
Insights
Anticoagulant therapy control was assessed in 732 patients over one year. Results show 85% of patients maintained therapeutic anticoagulation, with long-term patients achieving better control than short-term patients.
Area of Science:
- Clinical Medicine
- Pharmacology
- Public Health
Background:
- Anticoagulant therapy is crucial for preventing thromboembolic events.
- Effective management requires maintaining patients within a narrow therapeutic range.
- Quality control of anticoagulant treatment is essential for patient safety and clinical benefit.
Purpose of the Study:
- To evaluate the quality of anticoagulation control in two clinical settings over one year.
- To assess the percentage of time patients spent within the therapeutic range.
- To compare anticoagulation control between long-term and short-term treated patients.
Main Methods:
- Retrospective analysis of treatment data from 732 patients over 430 patient-years.
- Assessment of time within the therapeutic range (British ratio 2.0-4.0).
- Categorization of control as within therapeutic range, under-anticoagulated, or overtreated.
Main Results:
- Overall, patients were within the therapeutic range 85% of the time.
- Long-term patients achieved better control (87% in range) compared to short-term patients (72% in range).
- Short-term patients were undertreated 25% of the time, while long-term patients showed superior control rates.
Conclusions:
- The study demonstrates a high standard of anticoagulation control, comparable to other reports.
- While generally effective, areas for improvement exist, particularly for short-term treatment.
- Implementing robust quality control measures is vital for maximizing clinical benefits of anticoagulation therapy.
Abstract:
The control achieved in two anticoagulant clinics over 1 year was studied. The result of 430 patient years of treatment in 732 patients was assessed. Overall, the patients were maintained in the therapeutic range (British ratio 2.0-4.0) 85% of the time, 'under-anticoagulated' 10% and 'overtreated' 5% of the time. Patients on long-term treatment had better control than those on short-term treatment (87 and 72% of time in therapeutic range, respectively). Short-term patients were 'undertreated' one quarter of the time. Assessment of the percentage of time individual patients spent within the therapeutic range was a useful index: 77% short-term patients and 99% long-term patients were controlled more than half the time; and 30% short-term plus 40% long-term patients were controlled all the time. Two complementary methods of assessing therapeutic control are used. The standard of control compares favourably with other reports, but shows areas where improvements can be made. For assessment of clinical benefit from anticoagulants, close quality control of treatment by such methods is essential.